Notably, while HRDlow sarcoma cells formed RAD51 nuclear foci upon olaparib- and trabectedin-induced DNA damage, neither formation of RAD51 nuclear foci nor increased RAD51 nuclear intensity were observed in HRDhigh sarcoma cells and BRCA1-mutated ovarian cancer cells (Fig. 3a). The gene discussed is RAD51; the disease is ovarian carcinoma.